Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Gastric Cancer: early-phase trial registry
72 of 159 indexed Gastric Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #69 of 28,707 conditions by registered trial count.
159 US clinical trials · 72 currently recruiting · #69 of 28,707 conditions by registered trial count
Gastric Cancer: 159 US clinical trials tracked, 72 recruiting.
Gastric Cancer is the subject of 159 registered US clinical trials on ClinicalTrials.gov, 72 of them currently open to new participants. 17 are in Phase 3-4 (later-stage) and 118 in Phase 1-2 (earlier-stage). The most active sponsor is AstraZeneca, running 11 of these trials.
Enrollment posture brief
Registry condition gastric-cancer
OPEN 72 | RECR 45% | LATE 17 | EARLY 118 | RANK #69 | SPON 11
Volume-matched condition peers
Nearest open-share peer: Non-Small Cell Lung Cancer (45% recruiting · 455 trials)
Gastric Cancer lists 72 open slots (45% of 159 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Gastric Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Gastric Cancer is recruiting above its size-band peers.
72 of 159 indexed trials (45.3%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Gastric Cancer trials is spread across many organizations.
AstraZeneca accounts for 11 of 159 trials (6.9%). 107 distinct sponsors appear on at least one study for this condition label.
-
Typical Gastric Cancer enrolment sits around 117 participants.
Median target enrolment is 117 among the 154 trials that report a genuine target (sentinel values excluded). 65 of those (42.2%) plan for fewer than 100 participants.
-
Gastric Cancer research is mostly interventional.
142 interventional and 17 observational studies make up this index (89.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
159 total, page 2 of 4
Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination with XELOX or Irinotecan in Patients with Advanced Gastric Cancer
Idience Co.
NCT04725994
CTNNA1 Familial Expansion Study
Abramson Cancer Center at Penn Medicine
NCT05126290
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Dren Bio
NCT06999187
IDOV-Immune for Advanced Solid Tumors
ViroMissile
NCT06910657
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
Blue Earth Diagnostics
NCT07432633
CONFIRM: Magnetic Resonance Guided Radiation Therapy
Brigham and Women's Hospital
NCT04368702
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
AstraZeneca
NCT06147037
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
Lumicell
NCT02584244
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
BioEclipse Therapeutics
NCT04282044
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Harry H Yoon
NCT04069273
Combination of TATE and PD-1 Inhibitor in Liver Cancer
Teclison
NCT03259867
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
University of California, Irvine
NCT06580002
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
Baylor College of Medicine
NCT03740256
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
Washington University School of Medicine
NCT05187182
Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT06109467
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
Christian Hinrichs
NCT05483491
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Tanabe Pharma America
NCT06943521
Avutometinib and Defactinib in Diffuse Gastric Cancer
Ryan H. Moy, MD, PhD
NCT06487221
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
Lantheus Medical Imaging
NCT06298916
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
University of Chicago
NCT04107077
Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients
Fox Chase Cancer Center
NCT05274048
Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™)
Cedars-Sinai Medical Center
NCT07124351
Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract
Memorial Sloan Kettering Cancer Center
NCT00582647
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Exelixis
NCT03170960
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
AstraZeneca
NCT04644068
Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
Amgen
NCT05052801
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
Amgen
NCT05111626
Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1
University of Miami
NCT07224035
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
M.D. Anderson Cancer Center
NCT05075993
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences
NCT04198766
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
Merus B.V.
NCT04868877
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
Poseida Therapeutics
NCT05239143
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
NGM Biopharmaceuticals
NCT04913337
First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer
TORL Biotherapeutics
NCT05156866
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors
Suzhou Transcenta Therapeutics Co.
NCT04396821
A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer
Astellas Pharma Global Development
NCT03505320
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Toray Industries
NCT03872947
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
AstraZeneca
NCT04931654
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Cybrexa Therapeutics
NCT04902872
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals
NCT05215574
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
ALX Oncology
NCT05002127
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
Qurient Co.
NCT05438420
Claudin18.2 CAR-T (CT041) in Patients with Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers
CARsgen Therapeutics Co.
NCT04404595
RCT of Mobile Apps & FitBit v. Usual Care
Weill Medical College of Cornell University
NCT03623464
A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010
Genentech
NCT05867121
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics
NCT05864144
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors
NextCure
NCT05572684
A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
NCT05789069
Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community-AIM 2
University of Miami
NCT07224048
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
NCT05238883
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 69 |
| Phase 2 | 49 |
| Phase 3 | 13 |
| Phase 4 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Gastric Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Gastric Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Gastric Cancer page
159 registered trials, 72 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 72 Gastric Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- AstraZeneca sponsors the most Gastric Cancer trials on record, review their full trial history before evaluating a specific study. See AstraZeneca's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Gastric Cancer condition card totals 159 registered trials; most-linked intervention Paclitaxel; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.